OncologyTube Professional - Patients Click Here
383,032 video views
VJHemOnc: Videos
11:12
CAR T-cells are a hot topic right now, with huge potential for transforming the treatment of various hematological malignancies, including lymphoma. Here, David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, chairs a discussion on the current landscape of CAR T-cell therapy in lymphoma at the International Workshop on...
by:VJHemOnc | 6 views
07:44
Lymphoma treatment is focusing increasingly on novel agents with specific targets. At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France, Laurie Sehn, MD, of the University of British Columbia, Vancouver, Canada, chaired a panel discussion on novel targets and agents in lymphoma. Targets discussed included...
by:VJHemOnc | 4 views
02:07
Somatic mutations can be used to inform diagnosis and prognosis, but they are also useful targets for novel therapies. Valeria Santini, MD, of the University of Florence, Florence, Italy, explains which mutations are receiving the most focus as therapeutic targets in myelodysplastic syndromes in this interview from the 2018 Society of Hematologic O...
by:VJHemOnc | 7 views
02:44
While myelodysplastic syndromes (MDS) represent a heterogeneous set of pathologies, a large proportion of MDS show similarity in somatic mutations. In this interview, which took place at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Valeria Santini, MD, of the Univer...
by:VJHemOnc | 9 views
02:14
If resistance occurs to second generation TKIs in chronic myeloid leukemia (CML) patients, what is the next best option? Here, Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, explores this important question. He highlights what data from the ENESTnd (NCT00471497) and ENEST1st (NCT0106...
by:VJHemOnc | 18 views
03:15
Venetoclax monotherapy has yielded disappointing results in acute myeloid leukemia (AML) because resistance develops along with the propagation of MCL1-expressing clones. Here, Marina Konopleva, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses different ways to inhibit MCL1 expressi...
by:VJHemOnc | 50 views
01:35
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to treat acute myeloid leukemia (AML) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Perl explains how the FLT3 inhibitors...
by:VJHemOnc | 17 views
02:41
FCR chemoimmunother​apy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent of novel drugs in the field however, Nitin Jain, MD, from the MD Anderson Cancer Center, Houston, TX, believes that this therapy could be improved upon. In this interview, recorded at the 2018 Society o...
by:VJHemOnc | 14 views
03:38
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the research in chronic lymphocytic leukemia (CLL) is somewhat behind. In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, William Wierda, MD, PhD, of the MD Anderson...
by:VJHemOnc | 29 views
01:52
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses a new concept in the pathophysiology of myelodysplastic syndromes (MDS): that inflammation can be an effective indicator for MDS and its progression. She explains how cytokine S1...
by:VJHemOnc | 5 views
dsfsd